STOCK TITAN

Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) 2025 Annual Meeting

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Bionano Genomics (BNGO) has announced its participation in the American College of Medical Genetics and Genomics (ACMG) Annual Meeting 2025, scheduled for March 18-22 in Los Angeles. The company will present extensive research on Optical Genome Mapping (OGM) applications through various sessions and posters.

A featured CME session titled 'Evolution of Cytogenomic Technology' will showcase OGM's real-world applications, featuring presentations from leading experts including:

  • Dr. Adam Smith (Labcorp) on OGM's role in hematological malignancy research
  • Dr. Laila El-Khattabi (Sorbonne) presenting CHROMAPS project results
  • Dr. Nikhil Sahajpal (Greenwood Genetic Center) discussing findings from clinical research cohorts
  • Dr. Rashmi Kanagal-Shamanna (MD Anderson) on integrated OGM approaches

The company notes it will operate with a reduced footprint to control expenses while maintaining a strong scientific presence.

Bionano Genomics (BNGO) ha annunciato la sua partecipazione al Meeting Annuale del Collegio Americano di Genetica Medica e Genomica (ACMG) 2025, in programma dal 18 al 22 marzo a Los Angeles. L'azienda presenterà ricerche approfondite sulle applicazioni della Mappatura Genomica Ottica (OGM) attraverso varie sessioni e poster.

Una sessione CME in evidenza intitolata 'Evoluzione della Tecnologia CitoGenomica' metterà in mostra le applicazioni pratiche dell'OGM, con presentazioni di esperti di spicco, tra cui:

  • Dr. Adam Smith (Labcorp) sul ruolo dell'OGM nella ricerca delle neoplasie ematologiche
  • Dr. Laila El-Khattabi (Sorbonne) che presenterà i risultati del progetto CHROMAPS
  • Dr. Nikhil Sahajpal (Greenwood Genetic Center) che discuterà i risultati di coorti di ricerca clinica
  • Dr. Rashmi Kanagal-Shamanna (MD Anderson) sugli approcci integrati all'OGM

L'azienda segnala che opererà con un'impronta ridotta per controllare le spese, mantenendo al contempo una forte presenza scientifica.

Bionano Genomics (BNGO) ha anunciado su participación en el Congreso Anual del Colegio Americano de Genética Médica y Genómica (ACMG) 2025, programado del 18 al 22 de marzo en Los Ángeles. La empresa presentará investigaciones extensas sobre las aplicaciones de Mapeo Genómico Óptico (OGM) a través de diversas sesiones y carteles.

Una sesión CME destacada titulada 'Evolución de la Tecnología CitoGenómica' mostrará las aplicaciones en el mundo real del OGM, con presentaciones de expertos líderes, incluyendo:

  • Dr. Adam Smith (Labcorp) sobre el papel del OGM en la investigación de malignidades hematológicas
  • Dr. Laila El-Khattabi (Sorbonne) presentando los resultados del proyecto CHROMAPS
  • Dr. Nikhil Sahajpal (Greenwood Genetic Center) discutiendo hallazgos de cohortes de investigación clínica
  • Dr. Rashmi Kanagal-Shamanna (MD Anderson) sobre enfoques integrados de OGM

La empresa señala que operará con una huella reducida para controlar gastos, manteniendo al mismo tiempo una fuerte presencia científica.

바이오나노 제노믹스 (BNGO)미국 의학 유전학 및 유전체학 회의 (ACMG) 2025 연례 회의에 참여한다고 발표했습니다. 이 회의는 3월 18일부터 22일까지 로스앤젤레스에서 열립니다. 회사는 광학 유전체 매핑 (OGM) 응용 프로그램에 대한 광범위한 연구를 다양한 세션과 포스터를 통해 발표할 예정입니다.

'세포유전체 기술의 발전'이라는 제목의 CME 세션에서는 OGM의 실제 응용 프로그램을 소개하며, 다음과 같은 주요 전문가들의 발표가 있을 것입니다:

  • Dr. Adam Smith (Labcorp) - OGM의 혈액 악성 종양 연구에서의 역할
  • Dr. Laila El-Khattabi (소르본느) - CHROMAPS 프로젝트 결과 발표
  • Dr. Nikhil Sahajpal (그린우드 유전 센터) - 임상 연구 집단의 발견에 대해 논의
  • Dr. Rashmi Kanagal-Shamanna (MD 앤더슨) - 통합 OGM 접근 방식에 대해

회사는 비용을 통제하기 위해 축소된 규모로 운영할 것이라고 밝혔으며, 강력한 과학적 존재감을 유지할 것입니다.

Bionano Genomics (BNGO) a annoncé sa participation à la Réunion Annuelle du Collège Américain de Génétique Médicale et de Génomique (ACMG) 2025, prévue du 18 au 22 mars à Los Angeles. L'entreprise présentera des recherches approfondies sur les applications de Cartographie Génomique Optique (OGM) à travers diverses sessions et affiches.

Une session CME en vedette intitulée 'Évolution de la Technologie Cytogénomique' mettra en avant les applications concrètes de l'OGM, avec des présentations d'experts de premier plan, notamment :

  • Dr. Adam Smith (Labcorp) sur le rôle de l'OGM dans la recherche sur les malignités hématologiques
  • Dr. Laila El-Khattabi (Sorbonne) présentant les résultats du projet CHROMAPS
  • Dr. Nikhil Sahajpal (Greenwood Genetic Center) discutant des résultats des cohortes de recherche clinique
  • Dr. Rashmi Kanagal-Shamanna (MD Anderson) sur les approches intégrées de l'OGM

L'entreprise indique qu'elle fonctionnera avec une empreinte réduite pour contrôler les dépenses tout en maintenant une forte présence scientifique.

Bionano Genomics (BNGO) hat seine Teilnahme an der Jahrestagung des American College of Medical Genetics and Genomics (ACMG) 2025 angekündigt, die vom 18. bis 22. März in Los Angeles stattfindet. Das Unternehmen wird umfangreiche Forschungen zu den Anwendungen der Optischen Genomkartierung (OGM) in verschiedenen Sitzungen und Postern präsentieren.

Eine hervorgehobene CME-Sitzung mit dem Titel 'Entwicklung der zytogenomischen Technologie' wird die praktischen Anwendungen von OGM vorstellen, mit Präsentationen von führenden Experten, darunter:

  • Dr. Adam Smith (Labcorp) über die Rolle von OGM in der Forschung zu hämatologischen Malignomen
  • Dr. Laila El-Khattabi (Sorbonne) präsentiert die Ergebnisse des CHROMAPS-Projekts
  • Dr. Nikhil Sahajpal (Greenwood Genetic Center) diskutiert Erkenntnisse aus klinischen Forschungsgruppen
  • Dr. Rashmi Kanagal-Shamanna (MD Anderson) über integrierte OGM-Ansätze

Das Unternehmen weist darauf hin, dass es mit einem reduzierten Fußabdruck arbeiten wird, um die Kosten zu kontrollieren, während es gleichzeitig eine starke wissenschaftliche Präsenz aufrechterhält.

Positive
  • Growing acceptance of OGM technology for routine use in clinical research
  • Expanding research applications across multiple critical medical areas
  • Collaboration with prestigious institutions and renowned experts
Negative
  • Company implementing cost reduction measures through smaller conference footprint

Featured Scientific Session: "Evolution of Cytogenomic Technology: Real-World Applications of Optical Genome Mapping in the Laboratory", an accredited continuing medical education (CME) session, with a panel of experts presenting research on OGM's clinical and translational applications.

  • Dr. Adam Smith (University of Toronto, Canada; currently at Labcorp, USA) will provide an overview of OGM’s evolution into an essential tool for hematological malignancy research and its role in research of pre- and post-natal constitutional genetic disease.
  • Dr. Laila El-Khattabi (Sorbonne University Hospitals and the Brain Institute, Paris, France) will share results from the CHROMAPS project, a multi-institutional European collaboration utilizing OGM to evaluate structural variations and aneuploidies in constitutional and reproductive disorders.
  • Dr. Nikhil S. Sahajpal (Greenwood Genetic Center, USA) will present OGM findings from three clinical research cohorts, including neural tube defects (NTDs), undiagnosed rare disorders, and prenatal cases.
  • Dr. Rashmi Kanagal-Shamanna (The University of Texas, MD Anderson Cancer Center, USA) will showcase an integrated approach combining OGM and targeted NGS for hematologic malignancies, as well as OGM’s emerging role in quality control for CAR-T cell-based immunotherapies.
  • Two additional scientific posters featuring results from OGM applications in cancer and in postnatal genetic disorders will be presented at the conference

SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting 2025 with a broad range of scientific content showcasing optical genome mapping (OGM) in key research areas, including hematological malignancies, constitutional genetic disorders, and rare genetic diseases.

ACMG’s Annual Meeting, to be held March 18-22, 2025, in Los Angeles, USA, brings together industry professionals, researchers, and leading experts in clinical genetics to share advancements in genomic technologies.

All scientific posters will be presented in Exhibit Halls DE. Poster presentations and scientific workshop sessions on OGM include:

SessionTitlePresenterPresented
Scientific SessionEvolution of Cytogenomic Technology: Real-World Applications of Optical Genome Mapping in the LaboratorySmith A., El Khatabi L., Sahajpal N., Kanagal-Shamanna R.March 19, 2025
1:30 PM-3:00 PM PT
Petree Hall C
Scientific SessionIntroduction to Optical Genome Mapping in Hematologic MalignanciesDr Adam Smith
(Labcorp, USA)
March 19, 2025
1:30 PM-1:45 PM PT
Petree Hall C
Scientific SessionCHROMAPS Prospective Study: Improving Structural Variation Diagnosis in Constitutional Diseases Using OGMDr Laila El-Khattabi
(Sorbonne University Hospitals and the Brain Institute, France)
March 19, 2025
1:45 PM-2:05 PM PT
Petree Hall C
Scientific SessionIdentifying Hidden Structural Variations with OGM in Rare DisordersDr Nikhil Sahajpal
(Greenwood Genetic Center, USA)
March 19, 2025
2:05 PM-2:25 PM PT
Petree Hall C
Scientific SessionUnleashing OGM for Advancing Precision Therapeutics and Empowering CAR TherapyDr Rashmi Kanagal-Shamanna
(MD Anderson Cancer Center, USA)
March 19, 2025
2:25 PM-2:45 PM PT
Petree Hall C
Round Table DiscussionEvolution of Cytogenomic Technology: Real-World Applications of Optical Genome Mapping in the LaboratorySmith A., El Khatabi L., Sahajpal N., Kanagal-Shamanna R.March 19, 2025
2:45 PM-3:00 PM PT
Petree Hall C


Poster NumberTitleAuthorsPresented
P733Improved Algorithms for Optical Genome Mapping Workflows in Constitutional Disease and Oncology ApplicationsPang A.March 20, 2025
10:30 AM-11:30 AM PT Exhibit Hall

P782A Complex Structural Rearrangement Resulting in Recurrent SCN1A Deletion Identified by Optical Genome MappingButler K.March 21, 2025
10:30 AM- 11:30 AM PT
Exhibit Hall


Erik Holmlin, PhD, president and chief executive officer of Bionano, added, “Our presence at ACMG 2025 reflects the growing impact of optical genome mapping in clinical research. Although we are operating with a smaller footprint, in order to reduce expenses, the OGM community has assembled an outstanding lineup of presentations from individuals at leading institutions, that showcase how OGM continues to drive research advancements in hematological malignancies, rare genetic disorders, and constitutional genomics. We believe the growth in data and content about OGM’s enhanced utility in the cytogeneticist’s toolbox reflects the acceptance of OGM for routine use. We are eager to hear from many well-known experts in the field, including Dr Adam Smith who is currently at Labcorp."

More details on Bionano’s conference events can be found https://bionano.com/events/

About Bionano

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.

For more information, visit www.bionano.com or www.bionanolaboratories.com.

Bionano products are for research use only and not for use in diagnostic procedures.

Forward-Looking Statements of Bionano

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “may,” “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: OGM’s utility for applications in cancer, rare genetic disease and constitutional disorder research and in the areas reported in the presentations given and the posters made available at ACMG’s 2025 Annual Meeting; the utility of OGM for cytogeneticists the utility and adoption of OGM for routine use; and the growth and adoption of OGM generally. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of adverse geopolitical and macroeconomic events, such as the ongoing conflicts between Ukraine and Russia and Israel and Gaza and uncertain market conditions, including bank failures, inflation, supply chain disruptions, and regional or global pandemics, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; the failure of OGM to prove useful in areas including applications in cancer, rare genetic disease and constitutional disorder research and in the areas reported in the presentations given and the posters made available at ACMG’s 2025 Annual Meeting; the failure of OGM to prove useful to cytogeneticists; the failure of OGM to be accepted for routine use; the failure of laboratories to adopt OGM generally; the ability of our OGM solutions to offer the anticipated benefits for and contributions to the areas reported in the presentations given and posters made available at the ACMG’s 2025 Annual Meeting; future study results contradicting the results reported in the presentations given and posters made available at the ACMG’s 2025 Annual Meeting; changes in our strategic and commercial plans; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; our ability to continue as a “going concern,” which requires us to manage costs and obtain significant additional financing to fund our strategic plans and commercialization efforts; our ability to consummate any strategic alternatives; the risk that if we fail to obtain additional financing we may seek relief under applicable insolvency laws; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2023 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com

Investor Relations:
David Holmes
Gilmartin Group
+1 (858) 888-7625
IR@bionano.com


FAQ

What research areas will be covered in Bionano's ACMG 2025 presentations for BNGO?

The presentations will cover OGM applications in hematological malignancies, constitutional genetic disorders, rare genetic diseases, and CAR-T cell immunotherapy quality control.

When and where is the ACMG 2025 Annual Meeting featuring BNGO's presentations?

The ACMG Annual Meeting will be held from March 18-22, 2025, in Los Angeles, USA.

What is the CHROMAPS project being presented at ACMG 2025 for BNGO?

CHROMAPS is a multi-institutional European collaboration using OGM to evaluate structural variations and aneuploidies in constitutional and reproductive disorders.

What cost-reduction measure is BNGO implementing at ACMG 2025?

Bionano is operating with a smaller footprint at the conference to reduce expenses while maintaining scientific content presentation.
Bionano Genomics Inc

NASDAQ:BNGO

BNGO Rankings

BNGO Latest News

BNGO Stock Data

8.12M
2.73M
0.11%
10.24%
18.54%
Medical Instruments & Supplies
Laboratory Analytical Instruments
Link
United States
SAN DIEGO